Skip to content
OpenCapital
Earnings
Screener
Charts
Portfolio
Pricing
Connect your AI
Get started
Toggle navigation menu
Stocks
BioCryst Pharmaceuticals
Business Segments
Business Segments
Acquired in-process research and development
Acquired in-process research and development
BioCryst Pharmaceuticals
·
Business Segments
·
1 segment
Breakdown
Segments
Business Segments
View metric
Quarterly
Annual
TTM
Segment
Q1 '26
Business Segments
$697.76M
Total
$697.76M